CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
Clinical trial NCT04758767 · COMPLETED
Trial details
- NCT number
- NCT04758767
- Sponsor
- CASI pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-22
- Primary completion
- 2023-01-19
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.